Clinical efficacy and safety of two different hematoporphyrin monomethyl ether‐mediated photodynamic therapy regimen in Chinese children with port‐wine stain

Abstract Hematoporphyrin monomethyl ether‐photodynamic therapy (HMME‐PDT) has achieved encouraging clinical outcomes in adult port‐wine stain (PWS). Optimal treatment option for children with PWS was minimal. To compare whether the clinical effectiveness of HMME‐PDT with the 5‐min (fast) administration treatment regimen (FATR) was better than the 20‐min (slow) administration treatment regimen (SATR) for PWS of children in vivo and in vitro. Thirty‐four children with PWS were divided into two groups including FATR and SATR. The two groups received three times HMME‐PDT, respectively. Treatment efficacy and safety were evaluated in vivo and in vitro . Erythema index (EI) was used to evaluate the clinical outcomes. Both FATR and SATR were effective and safe in children with PWS after HMME‐PDT. There were significance differences between the two groups in reductions of EI after the second treatment ( p < 0.001) and the third treatment ( p < 0.001) with HMME‐PDT. The serum HMME concentration reach the peak level at short time compare with SATR group. A significance increased superoxide levels were observed in FATR group compare to SATR groups in vitro ( p < 0.05). Our study suggested that HMME‐PDT was effective and safe for children with PWS, the therapy regimen with FATR was better in clinical efficacy than that of the SATR.